Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations
Abstract The human epidermal growth factor receptor 2 (HER2) alterations are significant genetic alterations in non-small cell lung cancer (NSCLC), encompassing mutations, amplifications, and protein overexpression. Despite the substantial progress of anti-HER2 targeted therapies in breast and gastr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06589-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849705281255112704 |
|---|---|
| author | Jiang Liu Jianhua Liu Jianhe Yu Qun Ren Yin Cai Dadong Chen Chuanjun Song |
| author_facet | Jiang Liu Jianhua Liu Jianhe Yu Qun Ren Yin Cai Dadong Chen Chuanjun Song |
| author_sort | Jiang Liu |
| collection | DOAJ |
| description | Abstract The human epidermal growth factor receptor 2 (HER2) alterations are significant genetic alterations in non-small cell lung cancer (NSCLC), encompassing mutations, amplifications, and protein overexpression. Despite the substantial progress of anti-HER2 targeted therapies in breast and gastric cancers, numerous challenges persist in the treatment of NSCLC with HER2 alterations. Presently, the options for NSCLC with HER2 alterations remain limited, with inferior efficacy observed using small molecule anti-tumor targeted agents and conventional chemotherapy. Antibody drug conjugates (ADCs), an organic combination of monoclonal antibodies and cytotoxic drugs targeting specific tumor cells, have revolutionized the treatment landscape of NSCLC with HER2 alterations. Extensive exploration of ADCs has been conducted across NSCLC patients with HER2 alterations, achieving notable efficacy in some populations. This review aims to delve into the biological characteristics and current treatment landscape of NSCLC with HER2 alterations, emphasizing the transformative research advancements surrounding ADCs. By highlighting these developments, we aspire to provide essential insights to enhance clinical practice and improve management strategies for NSCLC patients with HER2 alterations. |
| format | Article |
| id | doaj-art-e31f3e252a2b403d806aee681e17193f |
| institution | DOAJ |
| issn | 1479-5876 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj-art-e31f3e252a2b403d806aee681e17193f2025-08-20T03:16:31ZengBMCJournal of Translational Medicine1479-58762025-05-0123111010.1186/s12967-025-06589-xResearch advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterationsJiang Liu0Jianhua Liu1Jianhe Yu2Qun Ren3Yin Cai4Dadong Chen5Chuanjun Song6Department of Oncology, Xinghua People’s Hospital Affiliated to Yangzhou UniversityDepartment of Oncology, Xinghua People’s Hospital Affiliated to Yangzhou UniversityDepartment of Oncology, Xinghua People’s Hospital Affiliated to Yangzhou UniversityDepartment of Oncology, Xinghua People’s Hospital Affiliated to Yangzhou UniversityDepartment of Oncology, Xinghua People’s Hospital Affiliated to Yangzhou UniversityDepartment of Oncology, Xinghua People’s Hospital Affiliated to Yangzhou UniversityDepartment of Oncology, Xinghua People’s Hospital Affiliated to Yangzhou UniversityAbstract The human epidermal growth factor receptor 2 (HER2) alterations are significant genetic alterations in non-small cell lung cancer (NSCLC), encompassing mutations, amplifications, and protein overexpression. Despite the substantial progress of anti-HER2 targeted therapies in breast and gastric cancers, numerous challenges persist in the treatment of NSCLC with HER2 alterations. Presently, the options for NSCLC with HER2 alterations remain limited, with inferior efficacy observed using small molecule anti-tumor targeted agents and conventional chemotherapy. Antibody drug conjugates (ADCs), an organic combination of monoclonal antibodies and cytotoxic drugs targeting specific tumor cells, have revolutionized the treatment landscape of NSCLC with HER2 alterations. Extensive exploration of ADCs has been conducted across NSCLC patients with HER2 alterations, achieving notable efficacy in some populations. This review aims to delve into the biological characteristics and current treatment landscape of NSCLC with HER2 alterations, emphasizing the transformative research advancements surrounding ADCs. By highlighting these developments, we aspire to provide essential insights to enhance clinical practice and improve management strategies for NSCLC patients with HER2 alterations.https://doi.org/10.1186/s12967-025-06589-xHuman epidermal growth factor receptor 2HER2Non-small cell lung cancerAntibody drug conjugatesT-DM1T-DXd |
| spellingShingle | Jiang Liu Jianhua Liu Jianhe Yu Qun Ren Yin Cai Dadong Chen Chuanjun Song Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations Journal of Translational Medicine Human epidermal growth factor receptor 2 HER2 Non-small cell lung cancer Antibody drug conjugates T-DM1 T-DXd |
| title | Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations |
| title_full | Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations |
| title_fullStr | Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations |
| title_full_unstemmed | Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations |
| title_short | Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations |
| title_sort | research advancements of antibody drug conjugates in non small cell lung cancer with her2 alterations |
| topic | Human epidermal growth factor receptor 2 HER2 Non-small cell lung cancer Antibody drug conjugates T-DM1 T-DXd |
| url | https://doi.org/10.1186/s12967-025-06589-x |
| work_keys_str_mv | AT jiangliu researchadvancementsofantibodydrugconjugatesinnonsmallcelllungcancerwithher2alterations AT jianhualiu researchadvancementsofantibodydrugconjugatesinnonsmallcelllungcancerwithher2alterations AT jianheyu researchadvancementsofantibodydrugconjugatesinnonsmallcelllungcancerwithher2alterations AT qunren researchadvancementsofantibodydrugconjugatesinnonsmallcelllungcancerwithher2alterations AT yincai researchadvancementsofantibodydrugconjugatesinnonsmallcelllungcancerwithher2alterations AT dadongchen researchadvancementsofantibodydrugconjugatesinnonsmallcelllungcancerwithher2alterations AT chuanjunsong researchadvancementsofantibodydrugconjugatesinnonsmallcelllungcancerwithher2alterations |